For instance, ceramide-modifying enzymes, particularly glucosylceramide synthase (GCS), are upregulated during sorafenib treatment in hepatoma cells (HepG2 and Hep3B), decreasing ceramide-induced cell death activation and therefore conferring resistance to the sorafenib treatment. Here, UGCG is linked to hepatocellular carcinoma.